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Little is known about the role of the central
melanocortin system in the control of fuel me-
tabolism in peripheral tissues. Skeletal muscle
AMP-activated protein kinase (AMPK) is acti-
vated by leptin and serves as amaster regulator
of fatty acid b-oxidation. To elucidate an un-
identified role of the central melanocortin
system in muscle AMPK regulation, we treated
conscious, unrestrained mice intracerebroven-
tricularly with the melanocortin agonist MT-II
or the antagonist SHU9119. MT-II augmented
phosphorylation of AMPK and its target acetyl-
CoA carboxylase (ACC) independent of caloric
intake. Conversely, AMPK/ACC phosphoryla-
tion by leptin was abrogated by the coadminis-
tration of SHU9119 or in KKAy mice, which
centrally express endogenous melanocortin
antagonist. Importantly, high-fat-diet-induced
attenuation of AMPK/ACC phosphorylation in
leptin-overexpressing transgenic mice was not
reversed by central leptin but was markedly
restored by MT-II. Our data provide evidence
for the critical role of the central melanocortin
system in the leptin-skeletal muscle AMPK
axis and highlight the system as a therapeutic
target in leptin resistance.
INTRODUCTION
Leptin augments fatty acid b-oxidation in skeletal muscle
and enhances whole-body insulin sensitivity, thereby
serving as a promising therapeutic candidate for the treat-
ment of insulin resistance and dyslipidemia (Shimabukuro
et al., 1997; Minokoshi et al., 2002). In agreement with this
notion, we and others have demonstrated the clinical effi-cacy of leptin in the treatment of diabetes, dyslipidemia,
and steatosis in patients with lipodystrophy (Oral et al.,
2002; Ebihara et al., 2007). The clinical application of leptin
has been hampered, however, by the fact that leptin does
not fully exert its metabolic effect in prevalent forms of
human obesity (Maffei et al., 1995) and in diet-induced
obese rodents (El-Haschimi et al., 2000).
Using transgenic skinny mice overexpressing leptin in
liver (LepTg mice), we recently demonstrated that en-
hanced lipid metabolism and insulin sensitivity in LepTg
mice are attenuated on a high-fat diet (HFD) (HFD-LepTg)
despite persistent hyperleptinemia, compared with HFD-
fed nontransgenic (HFD-non-Tg) littermates (Tanaka
et al., 2005). Even with pronounced hyperleptinemia, skel-
etal muscle AMPK activity is attenuated in HFD-LepTg
mice to the level of HFD-non-Tg mice (Tanaka et al.,
2005). Noteworthy is the fact that switching HFD back to
a standard diet (STD) leads to a significant recovery of
muscle AMPK activity in LepTg mice before they regain
their skinny phenotype (Tanaka et al., 2005), suggesting
the reversible nature of the dietary lipid-induced leptin
resistance.
AMPK is activated by decreased energy stores and
orchestrates energy-sparing reactions in a cell-specific
manner (Hardie et al., 2006). In skeletal muscle cells,
AMPK activation stimulates glucose uptake, glycolysis,
fatty acid b-oxidation, and mitochondrial biogenesis (Har-
die et al., 2006) and critically mediates leptin-induced
fatty acid b-oxidation (Minokoshi et al., 2002). Our previ-
ous work demonstrated that skeletal muscle AMPK activ-
ity closely parallels insulin sensitivity and inversely corre-
lates with energy efficiency in LepTg mice under STD or
HFD feeding (Tanaka et al., 2005), indicating that AMPK
activity should be a novel biochemical marker of leptin
sensitivity in vivo.
The central melanocortin system consists of endoge-
nous melanocortin agonists and receptors. Endogenous
agonist is synthesized as pro-opiomelanocortin (POMC)
preprohormone and is proteolytically cleaved to produce
melanocyte-stimulating hormones (MSHs). In the brain,Cell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Inc. 395
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Melanocortin in Leptin-Skeletal Muscle AMPK AxisFigure 1. Establishment of the Experi-
mental Protocol
(A) After intracerebroventricular (i.c.v.) and
subcutaneous (s.c.) cannula implantation,
mice were acclimatized and trained for han-
dling. On the day of sampling, agents were
administered i.c.v. in free-moving nonanesthe-
tized mice. Food intake was measured and
anesthesia was introduced s.c.
(B) Representative blots for phospho-AMPK
and AMPKa in soleus muscle after leptin
(0.5 mg) i.c.v. under intraperitoneal (i.p.) anes-
thesia. Muscles were sampled after another
i.p. injection of the anesthetic agent.
(C) Representative blots for phospho-AMPK
and AMPKa using the protocol in (A).POMC is principally expressed in the arcuate nucleus of
the hypothalamus (ARC) and the nucleus of the solitary
tract (NTS) of the brainstem (Schwartz et al., 1997). The
majority of POMC-expressing neurons in the ARC coex-
press functional leptin receptor and mediate the anorectic
effect of leptin (Cowley et al., 2001; Seeley et al., 1997). Al-
though mouse models and human subjects with defective
melanocortin signaling develop obesity (Huszar et al.,
1997; Fan et al., 1997; Kobayashi et al., 2002; Farooqi
et al., 2003), it remains largely unknown whether the cen-
tral melanocortin system regulates fuel metabolism in
skeletal muscle. In this context, we demonstrate here
that the central melanocortin system is a critical mediator
of leptin-induced skeletal muscle AMPK activation. In
sharp contrast to leptin, melanocortin agonist retains its
AMPK-activating potency even in mice fed a HFD.
RESULTS
Assessment of Skeletal Muscle AMPK
Phosphorylation after Intracerebroventricular
Administration in Conscious, Unrestrained Mice
AMPK activity is readily altered by various stimuli such as
muscle contraction and ischemia (Hardie et al., 2006). To
obtain reproducible results, establishment of an elabo-
rately organized protocol was indispensable to minimize
nonspecific AMPK activation. Intracerebroventricular (i.c.v.)
and subcutaneous (s.c.) cannulae were implanted 14
and 7 days prior to the experiment, respectively, so that
body weight recovered to the level of nonoperated mice
on the sampling day (data not shown). Subcutaneous
instead of intravenous cannulation was used to avoid
a major weight loss. Agents were injected i.c.v. in well-
acclimatized, nonanesthetized, free-moving mice. Anes-
thesia was introduced gently through s.c. cannula, and
samples were obtained within 5 min (Figure 1A).
We first administered leptin i.c.v. under intraperitoneal
(i.p.) anesthesia and sampled muscle after another i.p.
injection of the anesthetic agent. By this method, we could
not see a reproducible increase in phospho-AMPK levels
by leptin (Figure 1B). In contrast, by the protocol in Fig-
ure 1A, leptin-induced increase in AMPK phosphorylation
was clear (Figure 1C). In addition, we could also measure396 Cell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Incfood intake, which was unaffected by anesthesia or by the
nervousness of the mouse, precisely.
Melanocortin Agonist Increases AMPK
Phosphorylation in Skeletal Muscle
Melanotan II (MT-II) is a potent melanocortin 3/4 receptor
(MC3R/4R) agonist (Fan et al., 1997). Although it is known
that central treatment with MT-II reduces food intake (Fan
et al., 1997), its effect on skeletal muscle fuel metabolism
has not been thoroughly addressed. We treated 8-week-
old male C57BL/6 mice with leptin (0.5 mg) or MT-II (3.5
mg) i.c.v. and sampled the soleus muscle 6 hr later. Leptin
i.c.v. significantly increased AMPK phosphorylation in the
soleus muscle (Figure 2A). Likewise, MT-II i.c.v. increased
phospho-AMPK levels by 69% ± 19% (p < 0.05 versus
vehicle, n = 7). Neither leptin nor MT-II altered AMPKa
protein levels, resulting in a 78% ± 14% (p < 0.05 versus
vehicle, n = 7) and 64% ± 20% (p < 0.05 versus vehicle,
n = 7) increase in phospho-AMPK/AMPKa ratio by leptin
and MT-II, respectively (Figure 2A).
ACC is an established target of AMPK in muscle (Hardie
et al., 2006). Phosphorylation of ACC by AMPK inhibits
ACC enzyme activity and reduces the production of
malonyl-CoA, thereby activating fatty acid b-oxidation
(Minokoshi et al., 2002). In the present study, ACC phos-
phorylation was also augmented by MT-II by 90% ± 28%
(p < 0.05 versus vehicle, n = 7) an increase comparable
to that by leptin (83% ± 12%) (p < 0.05 versus vehicle,
n = 7) (Figure 2B). Neither leptin nor MT-II i.c.v. altered
ACC protein levels (see Figure S1A in the Supplemental
Data available with this article online).
LepTg mice exhibit a more than 10-fold increase in
plasma leptin levels, a paucity of adipose tissue, and
enhanced glucose and lipid metabolism (Ogawa et al.,
1999). In LepTg mice, soleus muscle AMPK phosphory-
lation and ACC phosphorylation were substantially in-
creased compared with wild-type littermates (insets in
Figures 2A and 2B). The levels of AMPK and ACC phos-
phorylation in MT-II or leptin i.c.v.-treatedmice were com-
parable to those in LepTg mice.
AMPK phosphorylation was increased 2 hr after leptin
i.c.v. by 63% ± 11% (p < 0.05 versus vehicle, n = 7) and
maintained this level up to 6 hr (75% ± 10% increase).
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Melanocortin in Leptin-Skeletal Muscle AMPK AxisFigure 2. Increased Skeletal Muscle AMPK and ACC Phosphorylation after Intracerebroventricular MT-II Treatment
(A) Representative blots for phospho-AMPK and AMPKa in soleus muscle sampled 6 hr after MT-II (3.5 mg) or leptin (0.5 mg) i.c.v. The graph shows
quantification of phospho-AMPK divided by that of AMPKa (phospho-AMPK/AMPKa ratio). yp < 0.05 versus vehicle, n = 7. Inset: Blots for phospho-
AMPK and phospho-AMPK/AMPKa in LepTg mice. *p < 0.05 versus non-Tg, n = 6. In this and all other figures, error bars represent ± SEM.
(B) Representative blots for phospho-ACC in soleus muscle 6 hr after MT-II or leptin i.c.v. yp < 0.05 versus vehicle, n = 7. The graph shows the quan-
tified data. Inset: Phospho-ACC in LepTg. #p < 0.05 versus non-Tg, n = 6.
(C) Phospho-AMPK/AMPKa before and 2 and 6 hr after MT-II or leptin i.c.v.B, vehicle; d, leptin;:, MT-II; *p < 0.05 versus vehicle, n = 6.
(D) Cumulative food intake over 6 hr. *p < 0.05 versus vehicle, yp < 0.05 versus leptin, n = 7.
(E) Blots for phospho-AMPK and AMPKa, and graph showing phospho-AMPK/AMPKa in MT-II-treated mice and vehicle-treated mice pair-fed with
MT-II-treated counterparts. *p < 0.05 versus vehicle, yp < 0.05 versus MT-II, n = 6.(p < 0.05 versus vehicle, n = 7) (Figure 2C). Likewise, MT-II
i.c.v. led to a significant increase in AMPK phosphoryla-
tion over 2 hr, by 100% ± 7% (p < 0.05 versus vehicle,
n = 7), and this level was maintained until the 6 hr point
(125% ± 12% increase) (p < 0.05 versus vehicle, n = 7)
(Figure 2C). To determine whether increased AMPK phos-
phorylation is paralleled by any change in plasma glucose
or insulin levels, mice were fasted for 3 hr, MT-II was in-
jected i.c.v., and blood samples were obtained 6 hr later.
No difference was observed in plasma glucose (vehicle
122 ± 12 mg/dl versus MT-II 125 ± 9 mg/dl; not significant
[NS], n = 6) or insulin (vehicle 1.84 ± 0.10 ng/ml versus
MT-II 1.77 ± 0.08 ng/ml; NS, n = 6) levels between vehicle-
and MT-II-treated mice.
Leptin orMT-II i.c.v. suppressed food intake (Figure 2D).
Over 6 hr, mice treated with leptin i.c.v. consumed 0.11 ±
0.05 g of food (p < 0.05 versus vehicle), while vehicle-
treated mice consumed 0.32 ± 0.08 g. Mice treated with
MT-II i.c.v. consumed 0.02 g with a standard deviation
of less than 0.01 g (p < 0.05 versus vehicle, p < 0.05 versus
leptin, n = 7). To rule out possible involvement of the ano-
rectic effect of MT-II in increased AMPK phosphorylationCin the muscle, we pair-fed vehicle-treated mice with mice
treated with MT-II. In contrast to MT-II-treated mice,
AMPK phosphorylation was not altered in the pair-fed
mice (p < 0.05 versus vehicle, n = 6) (Figure 2E), showing
that MT-II-induced AMPK phosphorylation is independent
of suppression of food intake.
We next examined whether peripheral MT-II administra-
tion has a similar effect on skeletal muscle AMPK. We
administered a single dose ofMT-II (10 mg, s.c.) and exam-
ined AMPK and ACC phosphorylation 6 hr later. Peripheral
treatment with MT-II at this dose also significantly in-
creased AMPK (61%± 19%) and ACC (69%± 20%) phos-
phorylation compared with vehicle (p < 0.05 versus vehi-
cle, n = 5) (data not shown).
Leptin-Induced AMPK and ACC Phosphorylation
Is Attenuated by Melanocortin Antagonism
Leptin activates the hypothalamic melanocortin pathway
(Schwartz et al., 1997; Cowley et al., 2001) and enhances
skeletal muscle AMPK activity (Minokoshi et al., 2002). To
test whether the central melanocortin system is involved in
leptin-induced AMPK activation in themuscle, we injectedell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Inc. 397
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Melanocortin in Leptin-Skeletal Muscle AMPK AxisFigure 3. Attenuation of Leptin-Induced Muscle AMPK and ACC Phosphorylation by Pharmacologic or Genetic Melanocortin
Blockade
(A, C, D, and F) Blots for phospho-AMPK and AMPKa, and graph showing phospho-AMPK/AMPKa.
(B, E, and G) Blots for phospho-ACC and quantified data.
Coadministration of SHU9119 (1.0 mg) i.c.v. attenuated leptin (0.5 mg)-induced increase in AMPK (A) and ACC (B) phosphorylation (yp < 0.05 versus
vehicle, zp < 0.05 versus leptin, n = 7). Phospho-AMPK/AMPKa was not affected in mice treated with SHU9119 alone or in SHU9119-treated mice
pair-fed with vehicle-treated mice (A and C). Leptin i.c.v. significantly increased AMPK (D and F) and ACC phosphorylation (E and G) in KKmice, while
the increase was attenuated in both 6-week-old (D and E) and 10-week-old KKAy mice (F and G) (*p < 0.05 versus KK-vehicle, yp < 0.05 versus
KK-leptin, n = 6; data are % of KK-vehicle).SHU9119, a MC3R/4R antagonist (Fan et al., 1997). Co-
administration of SHU9119 i.c.v. (1.0 mg) suppressed
leptin-induced increase in AMPK (Figure 3A) and ACC
phosphorylation (Figure 3B) to the vehicle level (phospho-
AMPK/AMPKa 150% ± 49% increase by leptin versus
4% ± 10% increase by leptin + SHU9119; phospho-ACC
79% ± 13% increase by leptin versus 6% ± 34% increase
by leptin + SHU9119; p < 0.05, n = 7). Intracerebroventric-
ular injection of SHU9119 alone did not affect AMPK (5%±
9% decrease) or ACC (10% ± 12% increase) phosphory-
lation (Figures 3A and 3B). Central administration of
SHU9119 alone or in conjunction with leptin did not
change ACC protein levels (Figure S1B). SHU9119 i.c.v.
significantly increased food intake over the following 6 hr
(vehicle 0.35 ± 0.08 g versus SHU9119 0.49 ± 0.09 g;
p < 0.05, n = 6). To test the hypothesis that increased
food intake caused by SHU9119may play a role in skeletal
muscle AMPK regulation, we compared AMPK/ACC
phosphorylation in vehicle-treated mice, SHU9119-
treated mice, and SHU9119-treated mice pair-fed with
vehicle-treated mice. Neither treatment with SHU9119398 Cell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Inc.only nor treatment with SHU9119 plus pair-feeding had
any effect on AMPK (SHU9119 15% ± 12% increase,
SHU9119 plus pair-feeding 10% ± 10% increase versus
vehicle) (Figure 3C) or ACC phosphorylation (SHU9119
8% ± 10% decrease, SHU9119 plus pair-feeding 13% ±
5% versus vehicle; NS, n = 6) (data not shown).
KKAymice (Aymutants on a KK background) ectopically
express agouti protein, an endogenous melanocortin
receptor antagonist, throughout the body, including in
the hypothalamus, and exhibit progressive obesity in ad-
dition to yellow coat color (Lu et al., 1994). Here we used
preobese (6 weeks old, KK 29.0 ± 0.8 g versus KKAy
29.1 ± 1.0 g; NS, n = 10) and obese (10 weeks old, KK
35.7 ± 1.4 g versus KKAy 39.9 ± 1.0 g; p < 0.05, n = 14)
male KKAy mice to examine leptin-induced AMPK activa-
tion. The levels of AMPK and ACC phosphorylation were
not significantly different between control KK and KKAy
mice at either age (Figures 3D–3G). Leptin i.c.v. led to
a significant increase in AMPK (phospho-AMPK/AMPKa
90% ± 10% increase versus KK-vehicle; p < 0.05, n = 5)
and ACC phosphorylation (125% ± 25% increase versus
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Melanocortin in Leptin-Skeletal Muscle AMPK AxisFigure 4. Recovery of Skeletal Muscle AMPK and ACC Phosphorylation by Intracerebroventricular MT-II Treatment in Mice Fed
a High-Fat Diet
(A) Food intake over the 6 hr after i.c.v. injection in HFD-LepTg mice. *p < 0.05 versus vehicle, yp < 0.05 versus leptin, n = 7.
(B and D) Blots for phospho-AMPK and AMPKa, and graph showing phospho-AMPK/AMPKa ratio.
(C and E) Blots for phospho-ACC and quantified data.
(B–E) In HFD-LepTg mice, AMPK phosphorylation (B) and ACC phosphorylation (C) were decreased in comparison to STD-LepTg mice and were
comparable to HFD-non-Tg mice. In HFD-LepTg mice, leptin i.c.v. did not alter AMPK (B) or ACC phosphorylation (C). MT-II (3.5 mg) i.c.v. restored
AMPK (B) and ACC phosphorylation (C) in HFD-LepTg mice (*p < 0.05 versus HFD-LepTg-vehicle, yp < 0.05 versus HFD-LepTg-leptin, n = 7; data
are % of HFD-LepTg vehicle) and HFD-non-Tg mice (D and E) (*p < 0.05 versus HFD-non-Tg-vehicle, n = 5).KK-vehicle, p < 0.05, n = 5) in 6-week-old KK mice, while
the increase was attenuated in 6-week-old KKAy mice
(phospho-AMPK/AMPKa 15% ± 21% increase, phos-
pho-ACC 10%± 11% increase; p < 0.05 versus KK-leptin,
n = 5) (Figures 3D and 3E). ACC protein levels were not
different between 6-week-old KK and KKAy mice (Fig-
ure S1C). The results were similar in 10-week-olds, with
a significant leptin-induced increase in AMPK (phospho-
AMPK/AMPKa 85% ± 17% increase versus KK-vehicle;
p < 0.05, n = 7) and ACC phosphorylation (133% ± 28%
increase versus KK-vehicle; p < 0.05, n = 7) in KK mice
and a lack of change in KKAy mice by leptin (phospho-
AMPK/AMPKa 18% ± 3% increase, phospho-ACC
21% ± 32% decrease; p < 0.05 versus KK-leptin, n = 7)
(Figures 3F and 3G).
Central Treatment with MT-II Leads to Recovery
of HFD-Induced Attenuation in AMPK
and ACC Phosphorylation
LepTg mice exhibit decreased caloric intake and in-
creased energy expenditure (Ogawa et al., 1999; Tanaka
et al., 2005). Enhanced glucose tolerance, increased insu-
lin sensitivity, and lower plasma triglyceride in LepTg mice
are independent of reduced food intake (Ogawa et al.,
1999). Over 4 weeks on HFD, LepTg mice, which remainCsignificantly more hyperleptinemic than non-Tg mice
(176 ± 4 versus 78 ± 7 ng/ml), become as obese, glucose
intolerant, insulin resistant, and hyperlipidemic as non-Tg
mice (Tanaka et al., 2005). Muscle AMPK/ACC phosphor-
ylation is also attenuated (Tanaka et al., 2005).
To address the effect of central melanocortin activation
under HFD, we treated HFD-LepTg mice with MT-II. MT-II
i.c.v., but not leptin i.c.v., suppressed food intake in HFD-
LepTg mice (vehicle 0.52 ± 0.10 g, leptin 0.49 ± 0.05 g,
MT-II 0.28 ± 0.04 g; MT-II p < 0.05 versus vehicle or leptin,
n = 7) (Figure 4A). In HFD-LepTg mice, muscle AMPK
phosphorylation and ACC phosphorylation were signifi-
cantly decreased compared with STD-LepTg mice and
were comparable to HFD-non-Tg mice (Figures 4B and
4C). Of note, leptin i.c.v. in addition to transgenic hyper-
leptinemia did not augment AMPK (21% ± 14% increase,
NS) or ACC phosphorylation (8% ± 6% decrease, NS) in
HFD-LepTg mice (Figures 4B and 4C). In contrast, MT-II
i.c.v. effectively augmented AMPK (by 85% ± 13%; p <
0.05 versus HFD-LepTg vehicle) and ACC phosphoryla-
tion (by 139% ± 16%; p < 0.05 versus HFD-LepTg vehicle)
in HFD-LepTg mice (Figures 4B and 4C), suggesting that
MT-II is a potent AMPK activator in muscle even under
HFD. To confirm the results with LepTg mice, we treated
HFD-fed wild-type (non-Tg) mice with leptin or MT-IIell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Inc. 399
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a significant increase in muscle AMPK (leptin 8% ± 10%
decrease, NS; MT-II 64% ± 12% increase versus vehicle;
p < 0.05, n = 5) (Figure 4D) and ACC phosphorylation (lep-
tin 19% ± 25% increase, NS; MT-II 96% ± 20% increase
versus vehicle; p < 0.05, n = 5) (Figure 4E) in the wild-
type mice. ACC expression was not altered by HFD or
by HFD plus leptin or MT-II i.c.v. (Figure S1D).
DISCUSSION
Despite vigorous research, the question of why leptin
loses its lipid-mobilizing potency under HFD has not
been fully answered. Hypothalamic and peripheral induc-
tion of SOCS-3 (Bjorbaek et al., 1998; Howard et al., 2004;
Wang et al., 2005; Kievit et al., 2006) and decreased per-
meability of the blood-brain barrier (El-Haschimi et al.,
2000; Oh-I et al., 2005) have been implicated in attenuated
leptin receptor signaling and metabolic efficacy. A recent
study has demonstrated blunted hypothalamic AMPK as
well as STAT3 signaling in HFD-fed mice (Martin et al.,
2006). In the present study, neither transgenic hyperlepti-
nemia nor central leptin treatment increased skeletal mus-
cle AMPK phosphorylation under HFD. Notably, however,
central MT-II administration did increase skeletal muscle
AMPK phosphorylation in mice fed a HFD, indicating
a mechanism upstream of the central melanocortin sys-
tem that is responsible for the leptin resistance.
AMPK is a cellular fuel gauge activated by a variety of
stresses. To stably assess AMPK activity in skeletal mus-
cle, samples must be obtained quickly and deliberately.
Furthermore, surgical interventions such as i.c.v. or intra-
venous cannulation cause substantial weight loss during
the following week, making it more difficult to interpret
the results in terms of energy homeostasis. In this sense,
implementation of our devised protocol was instrumental
in showing that skeletal muscle AMPK phosphorylation
is regulated by the central melanocortin system. Phos-
phorylation of the a subunit of AMPK at Thr172 is tightly
correlated with AMPK activity in many experimental con-
ditions, including leptin-induced AMPK activation in the
skeletal muscle (Minokoshi et al., 2002). Increased phos-
phorylation of AMPK and ACC in parallel firmly suggests
increased AMPK activity in vivo.
In contrast to the effects of the central melanocortin
system on satiety, little is known about its impact on fuel
metabolism in the peripheral tissues. A recent study has
shown that MT-II i.c.v. increases basal and insulin-stimu-
lated glucose disposal and basal hepatic glucose produc-
tion (Heijboer et al., 2005). However, MT-II does not seem
to alter insulin-dependent suppression of hepatic glucose
production (Heijboer et al., 2005). Our data here demon-
strate that the administration of melanocortin agonist aug-
ments skeletal muscle AMPK and ACC phosphorylation.
Considering the crucial role of skeletal muscle AMPK in
the regulation of fatty acid b-oxidation (Minokoshi et al.,
2002), our data strongly suggest a metabolic link between
the central melanocortin system and skeletal muscle fatty
acid mobilization. On the other hand, we did not observe400 Cell Metabolism 5, 395–402, May 2007 ª2007 Elsevier Incany change in fasting plasma glucose or insulin levels
6 hr after MT-II i.c.v. Heijboer et al. (2005) also report an
absence of change in basal plasma glucose and insulin
levels following MT-II i.c.v. Further studies utilizing a com-
bination of glucose clamp and measurement of AMPK ac-
tivity may give a more accurate view of the temporal rela-
tionships between AMPK activation and skeletal muscle
glucose utilization. POMC neurons are chiefly present in
the ARC and NTS, while MC4R, a major melanocortin re-
ceptor involved in energy homeostasis, is widely distrib-
uted and present in the paraventricular hypothalamic nu-
cleus (PVN) and the dorsal motor nucleus of the vagus
(DMV) (Liu et al., 2003). Further studies are necessary to
specify which nuclei within the central melanocortin sys-
tem mediate skeletal muscle AMPK activation.
Leptin is a pleiotropic hormone, serving as a critical
regulator of energy homeostasis, reproduction, blood
pressure, and bone metabolism (Masuzaki et al., 1997;
Aizawa-Abe et al., 2000; Ducy et al., 2000). Although a cru-
cial role of thehypothalamicmelanocortin systemhasbeen
recognized in theanorexigenic effect of leptin, thematter of
which functions of leptin aremelanocortin dependent or in-
dependent still remains controversial. We previously re-
ported that hypertension in LepTg mice is not ameliorated
by SHU9119 i.c.v., implicating a melanocortin-indepen-
dent pathway in blood pressure control by leptin (Aizawa-
Abe et al., 2000). In terms of effects on glucose homeosta-
sis, a recent study has shown that enhancement in hepatic
gluconeogenesis by leptin is blocked by SHU9119 i.c.v.,
whereas leptin-dependent reduction in glycogenolysis is
not (Gutierrez-Juarez et al., 2004). Taking these previous
studies together, it is reasonable to postulate that meta-
bolic regulation by leptin is mediated by both melano-
cortin-dependent and -independent pathways. Here we
show that pharmacological (SHU9119) or genetic (KKAy)
blockade of the melanocortin receptor attenuates leptin-
dependent AMPK and ACC phosphorylation. These data
provide evidence that the leptin-skeletal muscle AMPK
axis is mediated by the central melanocortin system.
Leptin-induced augmentation of AMPK and ACC phos-
phorylation was attenuated in both 6-week-old and 10-
week-old KKAy mice. In 10-week-old obese KKAy mice,
decreasedAMPK response to leptinmaybepartly attribut-
able to the secondary effect of obesity. However, absence
of muscle AMPK activation was observed even in lean
6-week-old KKAy mice, further supporting the notion that
melanocortin signaling is necessary for leptin-induced
AMPK activation. In KKAymice, skeletal muscle phospho-
AMPK levels were not altered compared with KK mice
despite reported hyperphagia (Fan et al., 1997). Central
administration of SHU9119alonealso causeshyperphagia
(Fan et al., 1997) but did not alter skeletal muscle AMPK
phosphorylation in our present study. The discrepancy be-
tween food intake and AMPK phosphorylation may sug-
gest diverging pathways regulating satiety and skeletal
muscle AMPK activity.
A recent study has shown that peripheral, but not cen-
tral, administration of ciliary neurotrophic factor (CNTF),
another potent anorectic agent in HFD-fedmice, activates.
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like leptin, increases phospho-STAT3 in the ARC, the an-
orectic effect of CNTF remains intact in Mc4r knockout
mice (Marsh et al., 1999). Noting that the anorectic effect
of leptin is substantially attenuated in Mc4r knockouts
(Marsh et al., 1999), these data suggest that central signal-
ing cascades of leptin and CNTF are independent at the
level of the melanocortin system and that centrally
mediated AMPK activation in muscle is unique to the
leptin-melanocortin pathway.
A previous work (Pierroz et al., 2002) and ours here
demonstrate that MT-II suppresses food intake in mice
fed a HFD. Another paper published recently has shown
that leptin-induced a-MSH secretion from the ARC is
abrogated in obese mice fed a HFD (Enriori et al., 2007).
In the Enriori et al. study, the authors also showed that
Mc4r expression is reciprocally upregulated in PVN from
obese mice. These data further support our results show-
ing that MT-II remains effective in suppressing food intake
and activating skeletal muscle AMPK even under HFD.
Taken together, our findings reinforce the notion that
MT-II may be beneficial for the treatment of insulin resis-
tance, a pathology characterized by amyocellular lipid ex-
cess. However, since the results of the present study are
based mainly on data from i.c.v. injections, further studies
are necessary to explore the clinical efficacy of melano-
cortin agonists.
In conclusion, our data demonstrate that leptin-induced
skeletal muscle AMPK activation is at least partly medi-
ated by the central melanocortin system. In contrast to
leptin, AMPK activation by melanocortin agonist is pre-
served even under HFD. Our data provide an insight into
the central regulation of skeletal muscle AMPK activity
and suggest a possible recovery of skeletal muscle fatty




C57BL/6 (B6), KK, and KKAy mice were obtained from CLEA Japan.
Heterozygous LepTg and non-Tg littermates on a B6 background
(Ogawa et al., 1999) were used. Animals were maintained on STD
(F-2, 3.7 kcal/g, 12%of kcal from fat, source soybean, Funahashi Farm)
and a 14 hr light/10 hr dark cycle at 23C. HFD was from Research
Diets (D12493, 5.2 kcal/g, 60% of kcal from fat, source soybean/lard).
Animals were given free access to food and water unless otherwise
mentioned. Body weight and food intake were monitored for the ani-
mals’ well-being. Experiments were started between 6 and 8 weeks
of age, except for KK and KKAy experiments. HFD was administered
for 4 weeks. Cannulae (Plastics One) were inserted stereotactically
into lateral ventricles and fixed. On the sampling day, leptin (0.5 mg),
MT-II (3.5 mg), SHU9119 (1.0 mg), or a combination was administered
in 0.5 ml saline solution at around the start of the light period. The
weight of the food pellet at the start and at the end of the experiment
was measured with a microbalance (A&D). Five to ten g/kg chloral hy-
drate (Nakalai Tesque) was administered through s.c. cannula (PE20,
Becton Dickinson) 2 or 6 hr after i.c.v. injection, and the soleus muscle
was sampled. Successful i.c.v. delivery of the reagents was ensured
by injecting dye to every animal postmortem and omitting data from
those with inadequate distribution of the dye. Plasma glucose and
insulin levels were measured by Glucose C-II Test Wako (Wako PureCChemical Industries) and Insulin ELISA Kit (Morinaga). Animal ex-
periments were performed in accordance with the Kyoto University
guidelines for animal experiments and were approved by the Animal
Research Committee, Kyoto University Graduate School of Medicine.
Western Blots
Muscle sampleswere homogenized as described (Tanaka et al., 2005).
After denaturing, 15 mg per lane of protein was loaded on 10% and
4%–20% SDS-polyacrylamide gels for AMPK and ACC, respectively,
and transferred to PVDF membrane (PerkinElmer). Phosphospecific
antibodies were used for the detection of phospho-AMPK and
phospho-ACC. Antibodies were anti-phospho-Thr172 AMPKa, anti-
AMPKa (Cell Signaling Technology), and anti-phospho-Ser79 ACC
(Upstate). ECL Plus (Amersham), a LAS-1000 image analyzer, and
MultiGauge version 2.0 (Fujifilm) were used for detection and quantifi-
cation.
Statistical Analyses
Data are presented asmeans ± SEM. Comparisons between or among
animal groups were performed by Student’s t test or repeated analysis
of variance (ANOVA), where applicable, and completed by Fisher’s
probable least-significant-difference test.
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/5/5/
395/DC1/.
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